Eton Pharmaceuticals Raises Full-Year Revenue Guidance Following Strong Q1 Performance
Eton Pharmaceuticals reported a strong first-quarter performance with revenue rising 40% to $24.3 million and net income of $1.6 million, leading the company to raise its full-year revenue guidance from $110 million to over $120 million. The growth was driven by existing products like INCRELEX and ALKINDI, while new launches HEMANGEOL and DESMODA showed promising early traction.
Tickers: $ETON
Topics: financial performance pharmaceuticals product launches